<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000865</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG 330</org_study_id>
    <secondary_id>11302</secondary_id>
    <nct_id>NCT00000865</nct_id>
  </id_info>
  <brief_title>The Safety and Effects of 1592U89 Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected Infants and Children</brief_title>
  <official_title>A Phase I Safety and Pharmacokinetic Study of 1592U89 Alone and In Combination With Other Antiretroviral Agents in Infants and Children With HIV Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      To assess the steady state pharmacokinetic features, tolerance, and safety of orally&#xD;
      administered 1592U89, given alone or in combination with other antiretroviral medications, in&#xD;
      HIV infected infants and children. To establish doses of 1592U89 appropriate for future&#xD;
      pediatric Phase II/III clinical trials.&#xD;
&#xD;
      On the basis of the preclinical and clinical studies, 1592U89 appears to be a promising agent&#xD;
      for treatment of HIV infection in children, either as an alternative to currently employed&#xD;
      agents, or in combination therapy regimens. A liquid formulation of the drug is available;&#xD;
      thus concurrent development of 1592U89 for children and adults is possible.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      On the basis of the preclinical and clinical studies, 1592U89 appears to be a promising agent&#xD;
      for treatment of HIV infection in children, either as an alternative to currently employed&#xD;
      agents, or in combination therapy regimens. A liquid formulation of the drug is available;&#xD;
      thus concurrent development of 1592U89 for children and adults is possible.&#xD;
&#xD;
      In part 1, patients will receive 1592U89 monotherapy for 12 weeks. Patients will be assigned&#xD;
      initially to a low dose of 1592U89 (Dose A). Those patients who tolerate the drug for at&#xD;
      least six weeks without a toxicity of grade 3 or above attributable to study drug will have&#xD;
      their 1592U89 dose increased (Dose B). If none of those patients experience a life&#xD;
      threatening event attributable to study drug, subsequent enrollees will be assigned initially&#xD;
      to Dose B. In part 2, each participant will be assigned randomly (1:1:1:1) within their age&#xD;
      and Part 1 regimen stratum to one of the four agents: Zidovudine (ZDV), Stavudine (d4T),&#xD;
      Didanosine (ddI) or Lamivudine (3TC) in combination with 1592U89.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">April 1998</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>32</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abacavir sulfate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Stavudine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Didanosine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  IVIG.&#xD;
&#xD;
          -  Erythropoietin, granulocyte colony stimulating factor and granulocyte macrophage&#xD;
             colony stimulating factor (for management of hematologic toxicity).&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  Documented HIV-1 infection.&#xD;
&#xD;
          -  Laboratory evidence of immunosuppression or symptomatic HIV disease.&#xD;
&#xD;
          -  Parent or legal guardian able and willing to provide signed informed consent.&#xD;
&#xD;
        Prior Medication: Required:&#xD;
&#xD;
          -  HIV infected infants and children will be eligible for the trial if they have received&#xD;
             greater than 56 days of previous antiretroviral therapy.&#xD;
&#xD;
        NOTE:&#xD;
&#xD;
          -  Those children who participated in the single dose phase I study of 1592U89 and&#xD;
             satisfy all other criteria for inclusion may have received &lt;= 56 days of previous&#xD;
             antiretroviral therapy.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms and conditions are excluded:&#xD;
&#xD;
          -  Grade 3 or greater abnormalities in any toxicity monitoring laboratory tests at&#xD;
             baseline.&#xD;
&#xD;
          -  Presence of an acute opportunistic infection requiring therapy at the time of&#xD;
             enrollment.&#xD;
&#xD;
          -  Intractable or chronic diarrhea or vomiting.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Chemotherapy for active malignancy.&#xD;
&#xD;
          -  Concurrent use of antiretroviral agents other than those provided by the study,&#xD;
             biologic response modifiers, human growth hormone, systemic corticosteroids (&gt;= 14&#xD;
             days duration), probenecid, I.V. pentamidine, immunomodulators (other than intravenous&#xD;
             immunoglobulin), or other investigational drugs.&#xD;
&#xD;
        Patients with any of the following prior conditions or symptoms are excluded:&#xD;
&#xD;
        - History of intolerance to any of the study drugs.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>13 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kline M</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>Van Dyke R</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>Yogev R</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>Shenep J</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>Usc La Nichd Crs</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSD Maternal, Child, and Adolescent HIV CRS</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>920930672</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane/LSU Maternal/Child CRS</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>701122699</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bronx-Lebanon Hosp. IMPAACT CRS</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10457</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DUMC Ped. CRS</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>277103499</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Jude/UTHSC CRS</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>381052794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hosp. CRS</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Hughes W, McDowell J, L Adams, Flynn P, Hetherington S, Kline M, Shenep J, Yogev R, Lafon S. Evaluation of the novel nucleoside 1592U89 in a phase I safety and pharmacokinetics (PK) study in HIV-infected infants and children. Conf Retroviruses Opportunistic Infect. 1996 Jan 28-Feb 1;3rd:115</citation>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>Reverse Transcriptase Inhibitors</keyword>
  <keyword>Anti-HIV Agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Abacavir</mesh_term>
    <mesh_term>Didanosine</mesh_term>
    <mesh_term>Stavudine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

